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Objectives: Traumatic osteoarthritis (OA) is possibly augmented by effects from loss of sex hormones.
Salmon calcitonin is shown to reduce OA pathogenesis and bone resorption. We investigated the effects
of oral salmon calcitonin treatment and ovariectomy on cartilage and bone pathology in a traumatic OA
model.
Methods: Six groups with 10 7-month-old female Sprague Dawley rats each were subjected to bilateral
meniscectomy (MNX), ovariectomy (OVX) or Sham surgery and treated for 8 weeks with oral salmon
calcitonin (CT) or vehicle (V) in the following way: (1) ShamþV; (2) MNXþV; (3) MNXþ CT;
(4) OVXþV; (5) MNX/OVXþV; (6) MNX/OVXþ CT. Weights were recorded weekly and CTX-II was
measured in serum. At termination 56 days post-surgery, the right tibia was analyzed for changes in
articular cartilage thickness, extent of cartilage damage and subchondral bone changes in predeﬁned
zones, as recommended in the novel OARSI histopathology score.
Results: The combined MNX/OVX model produced a signiﬁcantly reduced cartilage thickness (P¼ 0.033)
in the outer zone (Z1) of the tibial plateau and increased calciﬁed cartilage damage (P¼ 0.0004) and
serum CTX-II (P¼ 0.003). Addition of OVX to MNX signiﬁcantly increased the width of matrix damage at
the surface (P¼ 0.025) and 50% cartilage depth (P¼ 0.004). Treatment with oral salmon calcitonin
counteracted the loss of cartilage thickness (P¼ 0.055), signiﬁcantly reduced subchondral bone damage
score (P¼ 0.019) and reduced the type II collagen degradation (P¼ 0.009).
Conclusions: Addition of ovariectomy augmented site-speciﬁc traumatic OA pathology, which was
reduced by oral salmon calcitonin treatment. Treatments for OA might ideally affect both bone and
cartilage.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is a degenerative joint disease where
progressive deterioration leads to destruction of joint structure and
eventually loss of joint function.
Anterior cruciate ligament transection (ACLT) in dogs1 and
partial medial meniscectomy (MNX) and ACLT in rat2,3 show
progressive development of disease with initial loss of superﬁcial
chondrocytes and cartilage ﬁbrillation, followed by type II collagen
degradation and cartilage erosion. Subchondral bone sclerosis is
visible at later stages of disease.
Ovariectomy abrupts estrogen production and increases bone
and cartilage turnover. Ovariectomy alone has been shown to: R.H. Nielsen, Nordic Biosci-
nmark. Tel: 45-44-52-52-03;
ielsen).
s Research Society International. Pproduce signs of OA in rats4,5 and to increase OA pathology in
traumatic OA models in the rabbit6 and the mouse7.
Recently, a novel histological scoring system was presented by
the osteoarthritis research society international (OARSI) Histopa-
thology Initiative8. The score recommends the use of quantitative
and qualitative measures on various tissues to assess joint
pathology.
Salmon calcitonin has been used for more than 30 years for the
treatment of metabolic bone diseases9. The 32-amino-acid peptide
hormone exerts a potent anti-resorptive effect by direct binding to
osteoclasts10e13 and directly affects chondrocytes14,15. When used
in animal models of OA, nasal calcitoninwas shown to reduce signs
of OA in both articular cartilage16,17 and subchondral bone1.
Recently, a new oral formulation of salmon calcitonin was devel-
oped15,18,19, which was demonstrated to be safe in clinical20 and
pre-clinical settings15. The carrier 5-CNAC is an enhancer of
gastrointestinal peptide administration and is used to protect the
salmon calcitonin from the acidic environment and facilitateublished by Elsevier Ltd. All rights reserved.
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biological function of the hormone20,21.
The primary objectives of the current study were to investigate
the effects of supplementary ovariectomy on pathology in a trau-
matic OA model, and to assess the effects of a preventive oral
salmon calcitonin treatment. Recommendations from a novel
histopathology score8 were used to evaluate cartilage and bone
pathology.Methods
Animals
Sixty female Sprague Dawley rats, 7 months of age, were
obtained from Taconic (Denmark). Animals were acclimatized,
weighed and stratiﬁed into six groups of 10 animals per group and
mean 95% conﬁdence interval (95%CI) body weights from
30918 g to 31416 g. Animals were housed two by two in
standard type III H cages with sawdust bedding and nesting
material in a Scantainer-plus (Scanbur, Sweden). They were fed ad
libitum with a standard diet (no. 1324, Altromin, Lage, Germany)
and had access to Milli-Q water ad libitum.Performance of bilateral partial medial meniscectomy, bilateral
ovariectomy and Sham surgery
Rats were anaesthetized by a subcutaneous Hypnorm (Veta-
Pharma, UK)/Dormicum (Roche, Switzerland) injection. Each
animal received both knee surgery (either MNX or Sham surgery)
and incision from the back (either OVX or Sham surgery). Both
knees of each animal were subjected to the same kind of surgery,
either partial medial meniscectomy (MNX) or Sham surgery
(Sham). For performance of MNX, the skin over the knees was
shaved and disinfected. The skin was penetrated and an insertion
made medial to the patella, dislocating the patella laterally and
providing access to the joint space. The anterior part of the
medial meniscus was removed using a scalpel and surgical scis-
sors. After relocation of the patella, the wound was closed with
vicryl 5/0 (polyglactin 910)-braided absorbable suture (Ethicon,
Edinburgh, UK). The skin was closed with staples (BD Biosciences,
USA). Care was taken to keep the operation area moist with
saline during the procedure. In Sham surgery, the meniscus was
left untouched.
For OVX surgery, an incision centrally on the lower back
provided access to both ovaries, which were removed. The wound
was closed with vicryl 3/0 (polyglactin 910)-braided absorbable
suture (Ethicon, Edinburgh, UK). For Sham OVX surgery, access to
the ovaries was performed, but the ovaries were left intact. Rimadyl
(Pﬁzer, Belgium), 5 mg/kg sc., was given once a day as analgesic for
the following 4 days post-surgery to all animals. All procedures
were approved by the Danish Animal Experiments Inspectorate.Drug substance and concentration
5-CNAC (8-(N-2-hydroxy-5-chlorobenzoyl)-amino-caprylic
acid) is a molecule based on the Eligen technology from Emi-
sphere21 and was used as a carrier to protect the salmon calcitonin
from degradation and to facilitate uptake from the gastrointestinal
tract. The used calcitonin was recombinant salmon calcitonin.
5-CNAC and salmon calcitonin were provided by Novartis, Basel,
Switzerland. The concentration of salmon calcitonin used in this
experiment was decided from previous experiments15.Experimental design and weight recordings
The animals in the six groups were subjected to surgery and
administered orally twice daily for 56 consecutive days post-
surgery either with vehicle control (V) (150 mg/kg 5-CNAC) or oral
salmon calcitonin (CT) (150 mg/kg 5-CNACþ 2 mg/kg salmon
calcitonin) in the following way: (1) ShamþV; (2) MNXþV; (3)
MNXþCT; (4) OVXþV; (5) MNX/OVXþV; (6) MNX/OVXþCT.
Medication was administered by oral gavage of compounds dis-
solved in Milli-Q water to ﬁnal concentrations of 30 mg/ml 5-CNAC
and 0.4 mg/ml salmon calcitonin. Weights of the animals were
recorded weekly and quantity of drug adjusted weekly according to
new weight recordings.
After 56 days post-surgery the animals were euthanized and the
knee joints were isolated. The right knee joints were used for
histology, and those results are included in this manuscript. The left
knee joints were reserved for other purposes.
Blood sampling, preparation of serum and measurement of CTX-II
Blood samples were drawn from overnight-fasted, CO2/O2-
anaesthetized animals exactly 3 h after the morning dosing on day
21, 42 and 56 post-surgery. Baseline samples were obtained in the
morning without prior dosing of compounds. Blood was collected
from the eye orbital sinus into plain tubes and left to coagulate at
room temperature for 30 min. Samples were centrifuged at 1500g
for 10 min and all liquid was transferred to a new plain tube.
Centrifugationwas repeated at 1500g for 10 min and the serumwas
collected into a new plain tube and stored at 20C until use.
Concentration of CTX-II in the serum was measured using the
Serum Pre-Clinical Cartilaps ELISA (IDS Nordic, Herlev, Denmark)
according to the manufacturer’s instructions.
Preparation of tissues, sectioning and staining
The right knee joint was isolated at euthanasia, and the entire
unopened knee was ﬁxated in 4% formaldehyde in Dulbecco’s
phosphate buffered saline (DPBS, BioWhittaker, USA), pH 7.4.
Subsequently, femur and tibia were carefully separated and the
tibia decalciﬁed in 15% ethylene diamine tetraacetic acid (EDTA),
pH 7.4. The tibia was parafﬁn-embedded, cut anterio-posterior into
5 mm sections and mounted on glass slides. After deparafﬁnization
and hydration, the sections were stained with Safranin O/Fastgreen
and counterstained with hematoxylin.
Histology
The recommendations in the novel scoring system provided by
the OARSI Histopathology Initiative were used for histological
assessment8. Digital images were obtained using an Olympus BX-
60 microscope and an Olympus camera. Using CorelDraw software
(Corel, USA), the medial tibial plateau was divided into three zones
of equal width with zone 1 (Z1) on the outside (medial edge of
joint), zone 2 (Z2) in the central part of the medial plateau and zone
3 (Z3) on the inside (adjacent to the central cruciate ligaments)
(Fig. 1). The ends of articular cartilage on the medial tibial plateau
deﬁned the outer borders.
The following procedure applies for the parameters non-calci-
ﬁed cartilage thickness, cartilage matrix loss width, subchondral
bone plate thickness and calciﬁed cartilage and subchondral bone
damage score described below: from each knee, sections from three
locations with 200 mm apart, from within the weight-bearing
middle part of the plateau, were analyzed. From measurements on
the three sections from each knee, a knee average was calculated.
Fig. 1. Outline of measurements: (A) the medial tibial plateau was divided into three zones of equal width with zone 1 (Z1) on the outside (adjacent to the synovium), zone 2 (Z2) in
the central part of the medial plateau and zone 3 (Z3) on the inside (adjacent to the central cruciate ligaments). Measurements for cartilage matrix loss width across the whole tibial
plateau at “surface”, “50% depth” and “tidemark” are indicated. (B) Yellow line: illustration of measurement of non-calciﬁed cartilage area for calculation of the average cartilage
thickness. Black lines: illustration of subchondral bone plate thickness measurements at 10 locations within Z2 on each section.
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group mean and 95%CI. Specimens were blinded to the reader.
Non-calciﬁed cartilage thickness
The area of non-calciﬁed articular cartilage was measured
within zones Z1, Z2 and Z3, using ImagePro (Media Cybernetics,
USA) [Fig. 1(B)]. Obtained area values were divided by the width of
the individual zone to adjust for size variation between animals,
thereby presenting the results as average cartilage thickness in
micrometers.
Cartilage matrix loss width
The width of collagen matrix loss was measured in relation to
the depth of full-thickness non-calciﬁed cartilage matrix [Fig. 1(A)].
The widths of lesions were measured at any surface matrix loss
(“Surface”), at 50% matrix loss compared to full-thickness matrix
(“50% depth”), and 100% loss of non-calciﬁed matrix, e.g., to the
tidemark (“tidemark”). Each recording was divided by the tibial
plateau width to adjust for size variation between specimens,
thereby presenting the cartilage matrix loss width as percentage of
the tibial plateau width.
Subchondral bone plate thickness
The length from the surface of the subchondral bone to the ﬁrst
margin of the bone marrow was measured at 10 locations within
the zone Z2 on each section [Fig. 1(B)], and from those values
a section-average was calculated. Three section averages from the
three non-consecutive sections from each knee were used to
calculate a knee average, and the knee averages were then used to
calculate a group average and 95%CI. Values are shown in
micrometers as mean 95%CI. The Z2 zone was used alone formeasurements as the width of the tibial plateau in Z1 and Z3 often
exceeded the width of the growth plate, and so those zones were
not applicable for measurements.Quantiﬁcation of calciﬁed cartilage and subchondral bone damage
Damage to the calciﬁed cartilage and subchondral bone was
scored using a numerical scale from 0 to 5, where 0¼ no changes
and 5¼ increased basophilia at the tidemark, increased fragmen-
tation at the tidemark and/or of the calciﬁed cartilage, increased
area of marrow mesenchymal changes, and collapse of articular
cartilage into the epiphysis. The most severe lesion on each section
was scored. Again, the knee-averages were used to produce a group
mean and 95%CI.Statistical analysis
Statistical evaluation was performed on carefully selected and
independent parameters to avoid type 1 errors. Statistics was per-
formed using SAS software (SAS, USA). Effects in the model system
was assessed by comparisons between the groups: ShamþV,
MNXþV, OVXþV and MNX/OVXþV. A Bartlett’s test was per-
formed to ensure homogeneity of variances in the groups, followed
by an analysis of variance (ANOVA) to see if differences between
group-means existed. If means were signiﬁcantly different, a Dun-
nett’s post-test was performed with the MNX/OVXþV group as
reference group. By use of the Dunnett’s post-test the statistical
results were adjusted for multiple comparisons. P-values from the
Dunnett’s test are shown in italic in the ﬁgures. Direct effects from
treatment with oral calcitonin were assessed using a Student’s
t-test between V-treated and CT-treated groups, e.g., MNXþV vs
MNXþCT and MNX/OVXþV vs MNX/OVXþCT. P-values from the
t-test are underlined in the ﬁgures.
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Number of observations included in the analysis
All 60 animals completed the study, but during sectioning for
histology, one specimen from each of the ShamþV and MNXþV
groups was lost. Thus, group means were calculated from 10 spec-
imen means, except from histological parameters in the Sham and
MNX groups, where group means were calculated from nine
specimen means.
Body weights of the animals
Before the start of the experiment the animals were stratiﬁed
into six groups with mean 95%CI body weights in grams from
30918 to 31416. At the end of the experiment theweights were
(mean 95%CI in grams): ShamþV 31418; MNXþV 31014;
MNXþCT 302 20; OVXþV 35418; MNX/OVXþV 34416;
MNX/OVXþCT 34126. Only the OVXþV group was signiﬁcantly
different from the ShamþV group at termination with a body
weight increase of 12.7% (P< 0.05) (data not shown).
Histology
Representative pictures of tibial plateaus stained with Safranin
O and Fast Green are shown in Fig. 2. The articular cartilage on
ShamþV (A) and OVXþV (D) tibias was intact. In MNXþV (B) and
MNXþCT (C), reduction in cartilage thickness was modest, but the
extent of erosion at the cartilage surface was pronounced, and
changes in the calciﬁed cartilage were detectable. Widespread andFig. 2. Representative histological sections from the weight-bearing part of the medial tibia
(D), MNX/OVXþ V (E) and MNX/OVXþCT (F). Sections were stained with Safranin O and
borders of cartilage erosion.profound cartilage erosion, and basophilia in the calciﬁed cartilage,
was observed on the tibias from the MNX/OVXþV group (E) on the
outside of the plateau, whereas these changes appeared reduced in
the MNX/OVXþCT group (F).
Width of the tibial plateau
The width of the tibial plateau from each section was measured
(Fig. 1). Values were (mean 95%CI in mm): ShamþV 1791102;
MNXþV 1872 94; MNXþCT 196474; OVXþV 1766 490
MNX/OVXþV 1900 38; MNX/OVXþCT 1923100. Statistical
evaluation showed signiﬁcant difference between the group-means
and as a function of that, individual measurements of non-calciﬁed
cartilage areas and cartilage matrix loss width were corrected for
the width of the individual zone or the tibial plateau, respectively.
Non-calciﬁed cartilage thickness
The average non-calciﬁed tibial cartilage thicknesswas quantiﬁed
within each of the three zones Z1, Z2 and Z3 and results are shown in
Fig. 3. In Z1, the cartilage thickness in the MNX/OVXþV group was
signiﬁcantly reduced by 49% (P¼ 0.033) compared to the ShamþV
and by 43% (P¼ 0.13) compared to theMNXþV group. No effect was
observed from OVX alone. As a function of salmon calcitonin treat-
ment, the difference between MNX/OVXþV and MNX/OVXþCT
was borderline signiﬁcant (P¼ 0.055), whereas no difference was
found between MNXþV and MNXþCT (P¼ 0.87). In Z2, cartilage
thickness in the MNX/OVXþV was reduced by 23% (P¼ 0.11) and
16% (P¼ 0.42) compared to ShamþV andMNXþV, respectively. No
signiﬁcant effects were observed from calcitonin treatment.l plateau. Pictures are from groups: Shamþ V (A), MNXþ V (B), MNXþCT (C), OVXþ V
Fast Green. The size bar of 500 mm (A) applies to all pictures. White arrows mark the
Fig. 3. Average non-calciﬁed cartilage thickness in Z1, Z2 and Z3. Areas of non-calciﬁed cartilage were measured within each zone and divided by the width of the zone to obtain
average cartilage thickness. Values are presented as meanþ 95%CI in micrometers. Z1: Shamþ V (78.2þ11.8), MNXþ V (69.3þ 34.4), MNXþCT (72.3þ 27.5), OVXþ V (77.5þ18.9),
MNX/OVXþ V (39.5þ 24.3) and MNX/OVXþCT (71.5þ 25.8). Z2: Shamþ V (204.4þ 26.9), MNXþ V (186.7þ 38.9), MNXþCT (188.8þ 41.2), OVXþ V (198.4þ 32.0), MNX/OVXþ V
(156.5þ 45.7) and MNX/OVXþCT (195.9þ 31.0). Z3: Shamþ V (207.8þ 29.6), MNXþ V (220.0þ 37.2), MNXþCT (146.6þ 40.0), OVXþ V (199.1þ40.1), MNX/OVXþ V
(247.3þ 40.8) and MNX/OVXþCT (266.0þ 17.5). P-values from the Dunnett’s test with MNX/OVXþ V as the reference group are shown in italic, P-values from the Student’s t-test
are underlined.
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increased in all groups except the OVXþV, compared to ShamþV.Cartilage matrix loss width
The extent of cartilage matrix loss across the tibial plateau was
assessed by quantiﬁcation of the length of erosion at cartilage
surface, 50% cartilage depth and at the tidemark. Results are shown
in Fig. 4. No erosion was measured on any of the sections from the
ShamþV and OVXþV groups. The effect from OVX was evident
when comparing MNXþV to the MNX/OVXþV; extent of damage
at the surface (P¼ 0.023) and 50% cartilage depth (P¼ 0.0067) was
signiﬁcantly increased and extent of damage at the level of the
tidemark (P¼ 0.13) was two-fold increased. Although treatment
with calcitonin did not produce signiﬁcant effects, the reduced
extent of damage at the surface (P¼ 0.58), 50% depth (P¼ 0.33) and
tidemark (P¼ 0.10), indicated a more potent effect from treatment
on the deeper layers of the cartilage.Fig. 4. Cartilage matrix loss width across the tibial plateau. Length of erosion at surface, 50%
OVXþ V groups did not show any erosion. Values are presented as meanþ 95%CI in percen
(54.1þ9.3), OVXþ V (0.0þ 0.0), MNX/OVXþ V (67.7þ 8.0) and MNX/OVXþCT (64.0þ 5
OVXþ V (0.0þ 0.0), MNX/OVXþ V (36.4þ13.6) and MNX/OVXþCT (27.4þ7.6). Tidemark:
MNX/OVXþ V (16.6þ 12.3) and MNX/OVXþCT (5.85þ 4.9). P-values from the Dunnett’s t
Student’s t-test are underlined.Subchondral bone plate thickness
The subchondral bone plate thickness was assessed by
measuring the length from the surface of the subchondral bone to
the ﬁrst margin of the bone marrow in the zone Z2. Results are
shown in Fig. 5. Neither surgery nor treatment with calcitonin
seemed to produce any difference between groups, and mean
thickness values for all groups were found in the small range
between 312 and 353 mm.Calciﬁed cartilage and subchondral bone damage
The join MNX/OVX surgery produced a highly signiﬁcant
increase in the damage score compared to ShamþV (P¼ 0.0004)
and OVXþV (P< 0.0001), and borderline signiﬁcant to MNXþV
(P¼ 0.054) (Fig. 6). A signiﬁcant effect from calcitonin treatment
was observed in the MNX/OVX model (P¼ 0.033), but not with
MNX alone (P¼ 0.68).depth and tidemark were measured and divided by the plateau width. Shamþ V and
t of the plateau width. Surface: Shamþ V (0.0þ 0.0), MNXþ V (56.4þ 6.1), MNXþCT
.8). 50% depth: Shamþ V (0.0þ 0.0), MNXþ V (12.0þ 11.5), MNXþCT (9.87þ 10.2),
Shamþ V (0.0þ 0.0), MNXþ V (6.37þ 7.2), MNXþCT (2.53þ 4.6), OVXþ V (0.0þ 0.0),
est with MNX/OVXþ V as the reference group are shown in italic, P-values from the
Fig. 5. Subchondral bone plate thickness. The average distance between upper sub-
chondral bone surface and underlying marrow lumen was measured in Z2. Values are
presented as meanþ 95%CI in micrometers: Shamþ V (332.9þ 28.6), MNXþ V
(350.3þ 49.7), MNXþCT (312.4þ 42.8), OVXþ V (323.1þ36.9), MNX/OVXþ V
(353.3þ 59.9) and MNX/OVXþCT (331.8þ 50.9). P-values from the Dunnett’s test with
MNX/OVXþ V as the reference group are shown in italic, P-values from the Student’s
t-test are underlined.
Fig. 7. Concentration of c-terminal telopeptide of type II collagen (CTX-II) measured in
serum. Serum was obtained at indicated time points and measured for the concen-
tration of CTX-II. Values are shown as meanþ 95%CI (pg/ml). The shown P-values are
from Student’s t-test.
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The type II collagen degradation was assessed by measuring the
concentration of CTX-II in the serum (Fig. 7). Compared to
ShamþV, CTX-II was signiﬁcantly increased in the OVXþV group
at 3 weeks (P¼ 0.003) and 6 weeks (P< 0.001) after surgery, and in
the MNX/OVXþV group 3 weeks after surgery (P¼ 0.009). CTX-II
levels in the MNXþV, MNXþCT and MNX/OVXþCT were not
different from the ShamþV group at any time point.
Discussion
We have investigated the effects of partial medial meniscectomy,
ovariectomy and oral salmon calcitonin treatment on non-calciﬁed
articular cartilage thickness, cartilagematrix losswidth, subchondral
plate thickness, calciﬁed cartilage and subchondral bone damage,Fig. 6. Calciﬁed cartilage and subchondral bone damage. On each section, the most
severe lesion within the calciﬁed cartilage and subchondral bone was assigned a score
from 0 to 5, where 0 represents no damage and 5 represents severe damage. Values are
presented as meanþ 95%CI: Shamþ V (0.21þ0.26), MNXþ V (0.93þ 0.46), MNXþCT
(0.80þ 0.57), OVXþ V (0.033þ 0.075), MNX/OVXþ V (1.78þ 0.95) and MNX/OVXþCT
(0.70þ 0.48). P-values from the Dunnett’s test with MNX/OVXþ V as the reference
group are shown in italic, P-values from the Student’s t-test are underlined.and type II collagen degradation in a traumatic OA model without
and with increased bone turnover. We found that (1) OA pathology
was site-speciﬁc and developed on the outer part of the tibial
plateau, (2) addition of OVX surgery to MNX surgery increased OA
pathology, (3) theMNX/OVXmodel produced a signiﬁcant reduction
in cartilage thickness and a signiﬁcant increase in cartilage matrix
loss width, calciﬁed cartilage and subchondral bone damage score
and type II collagen degradation and (4) treatment with oral salmon
calcitonin counteracted cartilage erosion and extent of matrix loss
and signiﬁcantly reduced type II collagen degradation anddamage to
the calciﬁed cartilage and subchondral bone.
The current data show that OVX surgery augmented OA
pathology inﬂicted by traumatic injury, as earlier studies have indi-
cated6,7. The extent of cartilage damage was signiﬁcantly increased
by addition of OVX, and both cartilage loss and damage to the
calciﬁed cartilage were pronounced. The response produced from
MNX alone was smaller than expected, however this does not
question the additive effect of OVX surgery. Importantly, signiﬁcant
cartilage loss in the combinedmodel (MNX/OVX) was found only on
the outer 1/3 of the medial plateau (Z1, adjacent to the synovium).
This was as expected8, as the outer zone (Z1) is subject to more
mechanical forces compared to the central (Z2) and inner (Z1) zones.
Unilateral knee surgery as a model is most common, but we have no
reason to believe that the present use of bilateral MNX has changed
the course ofOA, compared to other studies usingunilateral surgery8.
We found that OVX surgery alone produced no cartilage
pathology in evaluated parameters, which at ﬁrst glance contra-
dicts previous ﬁndings stating that the OVX model in rats is a vali-
dated model of postmenopausal OA4,15,22. The discrepancy,
however, is partly due to the fact that the present study includes
only extent of cartilage matrix loss, whereas previous studies only
investigated changes in the superﬁcial layer of the articular carti-
lage (ﬁbrillation)4. We found that serum CTX-II was not elevated
from MNX surgery alone, which could be explained by the
moderate cartilage erosion observed. A likely reason could also be
that cartilage erosion induced by traumatic injury alone releases
only small amounts of the CTX-II marker. This is supported by the
observation that even a much worsened erosion of the articular
non-calciﬁed cartilage in the MNX/OVXþV compared to the
OVXþV group did not give rise to a marked difference in serum
CTX-II concentrations between these groups. This indicates that
CTX-II could also be released from the calciﬁed cartilage, and that
a metabolism-mediated CTX-II release potentially is able to
disguise CTX-II released from the articular cartilage. As this study
illustrates, the use of old animals way past the age of skeletal
maturity can facilitate a marked distinction in biomarkers
produced from surgery or intervention. We were not able to detect
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sclerotic bone changes do not occur at later stages of the disease8.
Increased body weight due to OVX surgery was considered of no
importance to OA severity in this study, as the OVXþV group,
showing the largest weight increase, produced no signs of OA
pathology. However, obesity could potentially worsen traumatic
injury in other settings.
Other investigations suggest that OA could be linked to an
altered metabolic state affecting the systemic level of bone turn-
over, as the prevalence of OA in women is shown to increase
dramatically around the age of 50, coinciding with the start of
menopause and the loss of sex hormones23e27. Induction of
experimental osteoporosis by ovariectomy in monkeys5,28, rabbits6
and rodents22 has also shown that estrogen depletion results in
increased bone turnover, emergence of OA symptoms and aggra-
vation of OA progression. However, distinct effects of ovariectomy
arising from subchondral bone changes vs direct effects of estrogen
loss on cartilage health have not been dissociated by anyone so far.
The present study is the ﬁrst to show that an oral formulation of
salmon calcitonin is able to reduce OA cartilage pathology in
a traumatic OA rat model with increased bone turnover. These
chondroprotective effects of oral calcitonin are in general align-
ment with those published previously using various non-oral
formulations of calcitonin both in vitro and in vivo1,14,15,18,19,29.
Calcitonin is approved as anti-resorptive intervention for treat-
ment of osteoporosis. The hormone binds directly to receptors on
osteoclasts to reduce their resorptive activity10e13 and chondrocytes
display reduced matrix metalloproteinase (MMP) expression and
activity, as well as decreased type II collagen degradation when
exposed to very small concentrations of salmon calcitonin14.
Furthermore, calcitonin is shown to promote proliferationof isolated
articular chondrocytes and to stimulate proteoglycan synthesis30.
Badurski et al., were the ﬁrst to demonstrate that salmon calcitonin
reduced cartilage erosion and protected against cartilage glycosami-
noglycan loss in experimental OA31. Recently, Manicourt and
colleagues used the dog ACLT model and showed that calcitonin
reduced subchondral bone resorption and trabecular thinning, which
were speculated to be crucial factors in the reduction of cartilage
erosion. In addition, the authors concluded that direct effect of calci-
tonin on the articular cartilage was present, as they observed a signif-
icant increase in proteoglycan content in the non-operated knees1.
Clinical trials have conﬁrmed that an oral formulation of salmon
calcitonin and 5-CNAC is safe to use and preliminary evidence of
chondroprotective effects of calcitonin in clinical settings has been
presented in both postmenopausal and OA patients1,20,29,32. Hence
previous studies indicate that effects fromsalmoncalcitonin treatment
could be both bone and cartilage anti-catabolic and cartilage anabolic,
however, curative effects need to be shown in long-term clinical trials.
The role of the subchondral bone in OA pathology is heavily
debated, and an interesting question is how anti-resorptive treat-
ment alone would affect the course of disease. Alendronate,
a bisphosphonate, was used to inhibit bone degradation in a trau-
matic OA rat model, and was reported to improve cartilage
pathology3. However, CTX-II levels in serum showed that alendr-
onate directly affected cartilage metabolism, and effects cannot be
accredited to impact on subchondral bone alone.
The fact that calcitonin treatment was not able to reduce OA
pathology when MNX surgery was performed alone could be
explained by the modest response from the model, as this leaves
only a little window for treatment. The MNX/OVX model, however,
produced a larger window for treatment, and here oral salmon
calcitonin signiﬁcantly reduced the damage in the calciﬁed carti-
lage and subchondral bone. Cartilage loss from Z1 was borderline
signiﬁcantly reduced when compared directly to the corresponding
control group. An inclusion of more animals in this study wouldhave reduced the variance in the groups and likely would have
overcome the borderline signiﬁcance.
OVX surgery introduced a metabolic component into the system.
We speculate that depletion of estrogens from ovariectomy increased
the activity of catabolic enzymes22 and thatorally administered salmon
calcitonin inhibited MMP-mediated type II collagen degradation15,
thereby maintaining the structural strength of the cartilage matrix to
resist increased mechanical load induced from meniscectomy.
The present investigations used relevant parameters from the
novel OARSI Histopathology Initiative score8. The score successfully
applies user-friendly quantitative and qualitative measures to eval-
uate pathology, however, weighing the contribution of the different
parameters to compute a total joint score could be problematic, and
the parameters could be evaluated separately with advantage.
Perhaps the most descriptive parameter would be quantiﬁcation of
lost cartilage, as this would mimic a longitudinal study design. For
that the original articular cartilage surface must be estimated.
However, as the cartilage damage in the present studywasnon-focal,
with erosions extending primarily to the outer of the tibial plateau,
the estimation of original articular cartilage surface was found to be
not possible in this experiment. For this rat model, we recommend
no less than three non-consecutive sections from each knee to be
analyzed, considering the variation thatwas found inmeasurements.
In conclusion, our ﬁndings demonstrate that loss of cartilage
thickness and extent of cartilage damage is augmented when
ovariectomy is added to meniscectomy. Oral salmon calcitonin
treatment counteracted OA pathology in cartilage and bone, and
might prove curative effect in clinical trials.
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